Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RIVA-DM: Effectiveness and Safety of Rivaroxaban vs. Warfarin in Nonvalvular Atrial Fibrillation and Diabetes Mellitus: Analysis of Electronic Health Record Data

NCT04509193 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04509193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04509193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RIVA-DM: Effectiveness and Safety of Rivaroxaban vs. Warfarin in Nonvalvular Atrial Fibrillation and Diabetes Mellitus: Analysis of Electronic Health Record Data
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
August 21, 2020
Completion date
July 31, 2021
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation